Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. uri icon

authors

  • Dotan, Iris
  • Levy-Nissenbaum, Etgar
  • Chowers, Yehuda
  • Fich, Alexander
  • Israeli, Eran
  • Adar, Tomer
  • Shteingart, Shimon
  • Hermona Soreq, PhD
  • Goldin, Eran

publication date

  • January 1, 2016